


Ifw

| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT<br>(Under 37 CFR 1.97(b) or 1.97(c))  |                               |                     |                       | Docket No.<br>0112713-983 |                          |
|---|-------------------------------|---------------------|-----------------------|---------------------------|--------------------------|
| In Re Application Of: Smith et al.  |                               |                     |                       |                           |                          |
| Application No.<br>10/634,663   | Filing Date<br>August 5, 2003 | Examiner<br>Unknown | Customer No.<br>29200 | Group Art Unit<br>1651    | Confirmation No.<br>6356 |
| Title: INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A FLEXIBLE GAS PERMEABLE CONTAINER  |                               |                     |                       |                           |                          |
| Address to:<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, VA 22313-1450   |                               |                     |                       |                           |                          |
| 37 CFR 1.97(b)  |                               |                     |                       |                           |                          |
| 1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. |                               |                     |                       |                           |                          |
| 37 CFR 1.97(c)  |                               |                     |                       |                           |                          |
| 2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:   |                               |                     |                       |                           |                          |
| <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);   |                               |                     |                       |                           |                          |
| OR  |                               |                     |                       |                           |                          |
| <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).   |                               |                     |                       |                           |                          |

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
0112713-983

In Re Application: Smith et al



|                 |                |          |              |                |                  |
|-----------------|----------------|----------|--------------|----------------|------------------|
| Application No. | Filing Date    | Examiner | Customer No. | Group Art Unit | Confirmation No. |
| 10/634,663      | August 5, 2003 | Unknown  | 29200        | 1651           |                  |

**INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A FLEXIBLE GAS  
CONTAINER**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on July 14, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature of Person Mailing Correspondence

Renee Street

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Dated: July 14, 2004

\_\_\_\_\_  
Signature

Robert M. Barrett (Reg. No. 30,142)  
BELL, BOYD & LLOYD LLC  
P. O. Box 1135  
Chicago, Illinois 60690-1135  
(312) 807-4204

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Smith et al.  
Appl. No.: 10/634,663  
Conf. No.: 6356  
Filed: August 5, 2003  
Title: INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A  
FLEXIBLE GAS PERMEABLE CONTAINER  
Art Unit: 1651  
Examiner: Unknown  
Docket No.: 0112713-983

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references are included with this form.

**U.S. PATENT DOCUMENTS**

| <u>Document No.</u> | <u>Date</u>        | <u>Inventor</u>   |
|---------------------|--------------------|-------------------|
| 4,140,162           | February 20, 1979  | Gajewski et al.   |
| 4,222,379           | September 16, 1980 | Smith             |
| 4,496,361           | January 29, 1985   | Kilkson           |
| 4,588,401           | May 13, 1986       | Kilkson           |
| 4,631,055           | December 23, 1986  | Redl et al.       |
| 4,910,147           | March 20, 1990     | Bacehowski et al. |
| 4,939,151           | July 3, 1990       | Bacehowski et al. |
| 4,978,336           | December 18, 1990  | Capozzi et al.    |
| 5,272,074           | December 21, 1993  | Rubens            |
| 5,324,647           | June 28, 1994      | Rubens et al.     |
| 5,912,177           | June 15, 1999      | Turner et al.     |

|              |                    |                 |
|--------------|--------------------|-----------------|
| 5,935,847    | August 10, 1999    | Smith et al.    |
| 5,989,215    | December 23, 1999  | Delmotte et al. |
| 6,074,663    | June 13, 2000      | Delmotte et al. |
| 6,297,046    | October 2, 2001    | Smith et al.    |
| 2002/0131933 | September 19, 2002 | Delmotte        |

**OTHER DOCUMENTS**

Tisseel Engineering Fibrin Matrix Technology, The Fibrin Network in Tissue Engineering, Harnessing the Morphogenic Potential Of Regenerating Tissues, Baxter Healthcare Corporation.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC



BY

Robert M. Barrett  
Reg. No. 30,142  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
Phone: (312) 807-4204

Dated: July 14, 2004



**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
(Use several sheets if necessary)

PTO Form 1449

Atty Docket No.  
0112713-983

Application No.  
10/634,663

Applicant  
Smith et al.

Filing Date  
August 5, 2003

Group  
1651

**U.S. PATENT DOCUMENTS**

| Examiner's<br>Initials | Document<br>Number | Publication<br>Date | Inventor          | Class | Subclass | Filing Date<br>If<br>Appropriate |
|------------------------|--------------------|---------------------|-------------------|-------|----------|----------------------------------|
|                        | 4,140,162          | February 20, 1979   | Gajewski et al.   |       |          |                                  |
|                        | 4,222,379          | September 16, 1980  | Smith             |       |          |                                  |
|                        | 4,496,361          | January 29, 1985    | Kilkson           |       |          |                                  |
|                        | 4,588,401          | May 13, 1986        | Kilkson           |       |          |                                  |
|                        | 4,631,055          | December 23, 1986   | Redl et al.       |       |          |                                  |
|                        | 4,910,147          | March 20, 1990      | Bacehowski et al. |       |          |                                  |
|                        | 4,939,151          | July 3, 1990        | Bacehowski et al. |       |          |                                  |
|                        | 4,978,336          | December 18, 1990   | Capozzi et al.    |       |          |                                  |
|                        | 5,272,074          | December 21, 1993   | Rubens            |       |          |                                  |
|                        | 5,324,647          | June 28, 1994       | Rubens et al.     |       |          |                                  |
|                        | 5,912,177          | June 15, 1999       | Turner et al.     |       |          |                                  |
|                        | 5,935,847          | August 10, 1999     | Smith et al.      |       |          |                                  |
|                        | 5,989,215          | December 23, 1999   | Delmotte et al.   |       |          |                                  |
|                        | 6,074,663          | June 13, 2000       | Delmotte et al.   |       |          |                                  |
|                        | 6,297,046          | October 2, 2001     | Smith et al.      |       |          |                                  |
|                        | 2002/0131933       | September 19, 2002  | Delmotte          |       |          |                                  |

**FOREIGN PATENT DOCUMENTS**

| Examiner's<br>Initials | Document<br>Number | Publication<br>Date | Country | Class | Subclass | Translation |    |
|------------------------|--------------------|---------------------|---------|-------|----------|-------------|----|
|                        |                    |                     |         |       |          | Yes         | No |
|                        |                    |                     |         |       |          |             |    |
|                        |                    |                     |         |       |          |             |    |
|                        |                    |                     |         |       |          |             |    |
|                        |                    |                     |         |       |          |             |    |

| Examiner's<br>Initials | <b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>  |
|------------------------|--|
|                        | Tisseel Engineering Fibrin Matrix Technology, The Fibrin Network in Tissue Engineering, Harnessing the Morphogenic Potential Of Regenerating Tissues, Baxter Healthcare Corporation. |
|                        |  |

|  |                         |
|--|-------------------------|
| <b>Examiner:</b>   | <b>Date Considered:</b> |
| *Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                         |